
## Prof. Alexandra Teleki

Alexandra Teleki is an Associate Professor in Pharmaceutical Nanotechnology and Drug Development at the Department of Pharmacy and SciLifeLab at Uppsala University, Sweden. She received her MSc in Chemical Engineering from the Royal Institute of Technology (KTH) Stockholm, Sweden and her PhD in Mechanical and Process Engineering from ETH Zurich, Switzerland. Currently, she is co-director of Sweden Drug Delivery Center (SweDeliver), president of CRS Nordic Local Chapter and in 2020 she was awarded an ERC Consolidator Grant. Her research focuses on engineering of functional inorganic and lipid-based nanomaterials for the diagnosis and treatment of gastrointestinal diseases.



## Alessio Malfanti, PhD

Dr Alessio Malfanti is currently a senior Postdoctoral Researcher at the University of Louvain. Dr Malfanti's research interests are at the interface among polymer chemistry, nanomedicine and biology covering unmet clinical needs. He has focused his work on engineering polymer therapeutics for cancer immunotherapy, vaccine development and synergistic drug combination therapy in the context of "cold cancers" such as glioblastoma, breast cancer and metastatic melanoma.

## **5 Major publications:**

[1] G. Catania, G. Rodella, K. Vanvarenberg, V. Préat, <u>A. Malfanti</u>, Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival, Biomaterials, (2023) 122006.

[2] <u>A. Malfanti</u>, G. Catania, Q. Degros, M. Wang, M. Bausart, V. Préat, Design of Bio-Responsive Hyaluronic Acid–Doxorubicin Conjugates for the Local Treatment of Glioblastoma, Pharmaceutics, 14 (2022) 124.

[3] M. Bausart, V. Préat, <u>A. Malfanti</u>, Immunotherapy for glioblastoma: the promise of combination strategies, Journal of Experimental & Clinical Cancer Research, 41 (2022) 1-22.

[4] <u>A. Malfanti</u>, M. Bausart, K. Vanvarenberg, B. Ucakar, V. Préat, Hyaluronic acid-antigens conjugates trigger potent immune response in both prophylactic and therapeutic immunization in a melanoma model, Drug Delivery and Translational Research, (2023) 1-18.

[5] A. Lepland, <u>A. Malfanti</u>, U. Haljasorg, E.K. Asciutto, M. Pickholz, M. Bringas, S. Đorđević, L. Salumäe, P. Peterson, T. Teesalu, Depletion of Mannose Receptor–Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice, Cancer Research Communications, 2 (2022) 533-551.